Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults

NCT ID: NCT04752644

Last Updated: 2023-07-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 73 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-02-22
• Study Completion Date: 2021-11-02

Brief Summary

A Phase 2a, Randomised, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the Recombinant MVA-BN®-RSV Vaccine against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Participants

Conditions

RSV Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Group1: MVA-BN-RSV

Participants will receive one intramuscular injection of MVA-BN-RSV (nominal titre 5 x 10*8 Inf.U per 0.5 mL) given on day -28 before RSV challenge on day 0.

On day 0, intranasal challenge with RSV-A (Memphis 37b strain) virus will occur for all participants

Group Type: EXPERIMENTAL

MVA-mBN294B

Intervention Type: BIOLOGICAL

MVA-BN-RSV (nominal titre 5 x10\*8 Inf.U per 0.5 mL) as intramuscular injections. Liquid frozen suspension, single dose of 0.5ml.

Group 2: Placebo

Participants will receive one intramuscular injection of Tris-Buffered-Saline (0.5 mL) given on day -28 before RSV challenge on day 0.

On day 0, intranasal challenge with RSV-A (Memphis 37b strain) virus will occur for all participants

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

TBS (Placebo) as intramuscular injections (0.5ml)

Interventions

MVA-mBN294B

MVA-BN-RSV (nominal titre 5 x10\*8 Inf.U per 0.5 mL) as intramuscular injections. Liquid frozen suspension, single dose of 0.5ml.

Intervention Type: BIOLOGICAL

Placebo

TBS (Placebo) as intramuscular injections (0.5ml)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. An informed consent document signed and dated by the participant and the Investigator 2. Aged between 18 and 50 years old on the day of signing the consent form 3. In good health with no history, or current evidence, of clinically significant medical conditions, and no clinically significant test abnormalities that will interfere with participant safety, as defined by medical history, physical examination, (including vital signs), ECG, and routine laboratory tests as determined by the Investigator 4. A documented medical history prior to enrolment 5. The following criteria are applicable to female participants participating in the study.

1. Females of childbearing potential must have a negative pregnancy test prior to enrolment.

2. Females of non-childbearing potential:

3. Post-menopausal* females; defined as having a history of amenorrhea for >12 months with no alternative medical cause, and /or by FSH level >40mLU/mL, confirmed by laboratory.

4. Documented status as being surgically sterile (hysterectomy, bilateral salpingectomy and bilateral oophorectomyhysterectomy, bilateral salpingectomy and bilateral oophorectomy) 6. The following criteria apply to female and male participants:

a. Female participants of childbearing potential must use one form of highly effective contraception. Hormonal methods must be in place from at least 2 weeks prior to the first study visit. The contraception use must continue until 28 days after the date of viral challenge. Highly effective contraception is as described below: i. Established use of hormonal methods of contraception described below (for a minimum of 2 weeks prior to the first study visit). When hormonal methods of contraception are used, male are required to use a condom with a spermicide: ii. combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

1. oral 2. intravaginal 3. transdermal iii. progestogen-only hormonal contraception associated with inhibition of ovulation:

1. oral

2. injectable

3. implantable iv. Intrauterine device (IUD) v. Intrauterine hormone-releasing system (IUS) vi. Bilateral tubal ligation vii. Male sterilisation (with the appropriate post vasectomy documentation of the absence of sperm in the ejaculate) where the vasectomised male is the sole partner for that woman.

viii. True abstinence - sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant.

b. Male participants must agree to the contraceptive requirements below from the vaccination visit and continue until 28 days after the date of Viral challenge: i. Use a condom with a spermicide to prevent pregnancy in a female partner or to prevent exposure of any partner (male and female) to the IMP.

ii. Male sterilisation with the appropriate post vasectomy documentation of the absence of sperm in the ejaculate (please note that the use of condom with spermicide will still be required to prevent partner exposure). This applies only to males participating in the study.

iii. In addition, for female partners of childbearing potential, that partner must use another form of contraception such as one of the highly effective methods mentioned above for female participants.

i. True abstinence - sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant.

c. In addition to the contraceptive requirements above, male participants must agree not to donate sperm following discharge from Quarantine until 28 days after the date of Viral Challenge/last dosing with IMP (whichever occurs last).

7. Sero-suitable to the challenge virus, as defined in the study Analytical Plan.

Exclusion Criteria

1. History of, or currently active, symptoms or signs suggestive of upper or lower respiratory tract infection within 4 weeks prior to the first study visit

2. Any history or evidence of any other clinically significant or currently active systemic comorbidities including psychiatric disorders (includes participants with a history of depression and/or anxiety).

3. And/or other major disease that, in the opinion of the Investigator, may put the participant at undue risk, or interfere with a participant completing the study and necessary investigations (e.g autoimmune disease or immunodeficiency).

4. Participants who have smoked ≥10 pack years at any time [10 pack years is equivalent to one pack of 20 cigarettes a day for 10 years].

5. A total body weight ≤50 kg or Body Mass Index (BMI) ≤18 kg/m2 or ≥35kg/m2.

6. Females who:

1. Are breastfeeding, or

2. Have been pregnant within 6 months prior to the study.

7. History of anaphylaxis-and/or a history of severe allergic reaction or significant intolerance to any food or drug or vaccine, as assessed by the PI.

8. Venous access deemed inadequate for the phlebotomy and cannulation demands of the study

9. Any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx that may interfere with the aims of the study and in particular any of the nasal assessments or viral challenge, (historical nasal polyps can be included, but large nasal polyps causing current and significant symptoms and/or requiring regular treatments in the last month will be excluded).

10. Any clinically significant history of epistaxis (large nosebleeds) within the last 3 months of the first study visit and/or history of being hospitalized due to epistaxis on any previous occasion.

11. Any nasal or sinus surgery within 3 months of the first study visit.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Bavarian Nordic

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

hVIVO Services Limited

London, , United Kingdom

Countries

United Kingdom

References

Jordan E, Kabir G, Schultz S, Silbernagl G, Schmidt D, Jenkins VA, Weidenthaler H, Stroukova D, Martin BK, De Moerlooze L. Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine. J Infect Dis. 2023 Oct 18;228(8):999-1011. doi: 10.1093/infdis/jiad108.

Reference Type: DERIVED

PMID: 37079393 (View on PubMed)

Other Identifiers

RSV-MVA-015

Identifier Type: -

Identifier Source: org_study_id